8-K filing — Transcode Therapeutics, Inc. (RNAZ)
Filed: 2026-10-28 AccNo: 0001104659-26-119658 Size: 207 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
TransCode Therapeutics Retains Tungsten Advisors for Strategic Review
TransCode Therapeutics has engaged Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its lead therapeutic candidate, TTX-MC138, and its broader oncology portfolio.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TransCode Therapeutics To Present Poster Featuring TTX-MC138 ESMO Congress 2026
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for